Ameriprise Financial Inc. Acquires New Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Ameriprise Financial Inc. acquired a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 408,058 shares of the company's stock, valued at approximately $649,000. Ameriprise Financial Inc. owned 0.45% of Caribou Biosciences as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in Caribou Biosciences by 28.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock worth $3,360,000 after purchasing an additional 467,738 shares in the last quarter. Northern Trust Corp boosted its position in Caribou Biosciences by 3.4% during the 4th quarter. Northern Trust Corp now owns 714,737 shares of the company's stock valued at $1,136,000 after acquiring an additional 23,531 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Caribou Biosciences by 74.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company's stock valued at $297,000 after acquiring an additional 79,636 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Caribou Biosciences during the 4th quarter valued at $288,000. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Up 15.6%

Shares of NASDAQ:CRBU traded up $0.17 during trading on Friday, reaching $1.26. 2,027,432 shares of the company's stock traded hands, compared to its average volume of 1,401,168. Caribou Biosciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The firm has a market cap of $117.19 million, a PE ratio of -0.76 and a beta of 2.44. The company has a 50-day simple moving average of $0.89 and a 200-day simple moving average of $1.30.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $1.48 million. On average, equities research analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.